Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
First Online: 24 March 2026
Competing interests
: D.G. has received grants or research support (through ECOGENE-21) or consulting fees from 89Bio, Amgen, Arrowhead, AstraZeneca, CRISPRx, Eli Lilly, Ionis, Merck, New Amsterdam, Novartis, Regeneron, Sanofi, Ultragenyx and Verve. E.S.G.S. has received research support and consulting fees paid to his institution from Amgen, Menarini, Merck, Novartis, Novo Nordisk, Ionis and Ultragenyx. M.L. declares no competing interests.
